BioCentury
ARTICLE | Clinical News

Macitentan: Phase I started

February 27, 2012 8:00 AM UTC

Actelion disclosed in its 4Q11 earnings that it began an open-label, U.S. Phase I trial to evaluate oral macitentan given daily in combination with 150 mg/m 2 temozolomide every other week for 12 mont...